156 related articles for article (PubMed ID: 26846185)
21. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
Noyes K; Dick AW; Holloway RG;
Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
[TBL] [Abstract][Full Text] [Related]
22. Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites.
Stroupe KT; Weaver FM; Cao L; Ippolito D; Barton BR; Burnett-Zeigler IE; Holloway RG; Vickrey BG; Simuni T; Follett KA
Mov Disord; 2014 Nov; 29(13):1666-74. PubMed ID: 25220042
[TBL] [Abstract][Full Text] [Related]
23. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease.
Valldeoriola F; Morsi O; Tolosa E; Rumià J; Martí MJ; Martínez-Martín P
Mov Disord; 2007 Nov; 22(15):2183-91. PubMed ID: 17724747
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of pramipexole in Parkinson's disease in the US.
Hoerger TJ; Bala MV; Rowland C; Greer M; Chrischilles EA; Holloway RG
Pharmacoeconomics; 1998 Nov; 14(5):541-57. PubMed ID: 10344917
[TBL] [Abstract][Full Text] [Related]
25. [Pharmacoeconomic study of the treatment of advanced Parkinson's disease].
Vivancos-Matellano F; Garcia-Ruiz AJ; Garcia-Agua Soler N
Rev Neurol; 2016 Dec; 63(12):529-536. PubMed ID: 27897303
[TBL] [Abstract][Full Text] [Related]
26. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial.
Lhommée E; Wojtecki L; Czernecki V; Witt K; Maier F; Tonder L; Timmermann L; Hälbig TD; Pineau F; Durif F; Witjas T; Pinsker M; Mehdorn M; Sixel-Döring F; Kupsch A; Krüger R; Elben S; Chabardès S; Thobois S; Brefel-Courbon C; Ory-Magne F; Regis JM; Maltête D; Sauvaget A; Rau J; Schnitzler A; Schüpbach M; Schade-Brittinger C; Deuschl G; Houeto JL; Krack P;
Lancet Neurol; 2018 Mar; 17(3):223-231. PubMed ID: 29452685
[TBL] [Abstract][Full Text] [Related]
27. Cost-utility analysis of Parkinson's disease.
Shan DE; Wu HC; Chan LY; Liu KD
Acta Neurol Taiwan; 2011 Mar; 20(1):65-72. PubMed ID: 21249581
[TBL] [Abstract][Full Text] [Related]
28. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
Palmer CS; Nuijten MJ; Schmier JK; Subedi P; Snyder EH
Pharmacoeconomics; 2002; 20(9):617-28. PubMed ID: 12141889
[TBL] [Abstract][Full Text] [Related]
30. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
[TBL] [Abstract][Full Text] [Related]
31. Estimating the direct and indirect costs associated with Parkinson's disease.
Rodríguez-Blázquez C; Forjaz MJ; Lizán L; Paz S; Martínez-Martín P
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):889-911. PubMed ID: 26511768
[TBL] [Abstract][Full Text] [Related]
32. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden: an exploratory study.
Kristiansen IS; Bingefors K; Nyholm D; Isacson D
Appl Health Econ Health Policy; 2009; 7(3):167-80. PubMed ID: 19799471
[TBL] [Abstract][Full Text] [Related]
33. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs.
Charles PD; Padaliya BB; Newman WJ; Gill CE; Covington CD; Fang JY; So SA; Tramontana MG; Konrad PE; Davis TL
Parkinsonism Relat Disord; 2004 Dec; 10(8):475-9. PubMed ID: 15542007
[TBL] [Abstract][Full Text] [Related]
34. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
[TBL] [Abstract][Full Text] [Related]
35. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
Lowin J; Bergman A; Chaudhuri KR; Findley LJ; Roeder C; Schifflers M; Wood E; Morris S
J Med Econ; 2011; 14(5):584-93. PubMed ID: 21728911
[TBL] [Abstract][Full Text] [Related]
36. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
[TBL] [Abstract][Full Text] [Related]
37. Neuropsychological changes following deep brain stimulation surgery for Parkinson's disease: comparisons of treatment at pallidal and subthalamic targets versus best medical therapy.
Rothlind JC; York MK; Carlson K; Luo P; Marks WJ; Weaver FM; Stern M; Follett K; Reda D;
J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):622-9. PubMed ID: 25185211
[TBL] [Abstract][Full Text] [Related]
38. Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany.
Meissner W; Schreiter D; Volkmann J; Trottenberg T; Schneider GH; Sturm V; Deuschl G; Kupsch A
J Neurol; 2005 Feb; 252(2):218-23. PubMed ID: 15729530
[TBL] [Abstract][Full Text] [Related]
39. Prediction of depression and anxiety via patient-assessed tremor severity, not physician-reported motor symptom severity, in patients with Parkinson's disease or essential tremor who have undergone deep brain stimulation.
Achey RL; Yamamoto E; Sexton D; Hammer C; Lee BS; Butler RS; Thompson NR; Nagel SJ; Machado AG; Lobel DA
J Neurosurg; 2018 Dec; 129(6):1562-1571. PubMed ID: 29473781
[TBL] [Abstract][Full Text] [Related]
40. Deep brain stimulation improves survival in severe Parkinson's disease.
Ngoga D; Mitchell R; Kausar J; Hodson J; Harries A; Pall H
J Neurol Neurosurg Psychiatry; 2014 Jan; 85(1):17-22. PubMed ID: 23843542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
